Maintenance of neuronal TDP-43 expression requires axonal lysosome transport

Reviewer #1 (Public review):

Summary:

As TDP-43 mislocalization is a hallmark of multiple neurodegenerative diseases, the authors seek to identify pathways that modulate TDP-43 levels. To do this, they use a FACS based genome wide CRISPR KD screen in a Halo tagged TDP-43 KI iPSC line. Their screen identifies a number of genetic modulators of TDP-43 expression including BORC which plays a role in lysosome transport.

Strengths:

Genome wide CRISPR based screen identifies a number of modulators of TDP-43 expression to generate hypotheses regarding RNA BP regulation and perhaps insights into disease.

Weaknesses:

It is unclear how altering TDP-43 levels may relate to disease where TDP-43 is not altered in expression but mislocalized. This is a solid cell biology study, but the relation to disease is not clear without providing evidence of BORC alterations in disease or manipulation of BORC reversing TDP-43 pathology in disease.

The mechanisms by which BORC and lysosome transport modulate TDP-43 expression are unclear. Presumably, this may be through altered degradation of TDP protein but this is not addressed.

Previous studies have demonstrated that TDP-43 levels can be modulated by altering lysosomal degradation so the identification of lysosomal pathways is not particularly novel.

It is unclear whether this finding is specific to TDP-43 levels or whether lysosome localization may more broadly impact proteostasis in particular of other RNA BPs linked to disease.

Unclear whether BORC depletion alters lysosome function or simply localization.

Reviewer #2 (Public review):

Summary:

The authors employ a novel CRISPRi FACS screen and uncover the lysosomal transport complex BORC as a regulator of TDP-43 protein levels in iNeurons. They also find that BORC subunit knockouts impair lysosomal function, leading to slower protein turnover and implicating lysosomal activity in the regulation of TDP-43 levels. This is highly significant for the field given that a) other proteins could also be regulated in this way, b) understanding mechanisms that influence TDP-43 levels are significant given that its dysregulation is considered a major driver of several neurodegenerative diseases and c) the novelty of the proposed mechanism.

Strengths:

The novelty and information provided by the CRISPRi screen. The authors provide evidence indicating that BORC subunit knockouts impair lysosomal function, leading to slower protein turnover and implicating lysosomal activity in the regulation of TDP-43 levels and show a mechanistic link between lysosome mislocalization and TDP-43 dysregulation. The study highlights the importance of localized lysosome activity in axons and suggests that lysosomal dysfunction could drive TDP-43 pathologies associated with neurodegenerative diseases like FTD/ALS. Further, the methods and concepts will have an impact to the larger community as well. The work also sets up for further work to understand the somewhat paradoxical findings that even though the tagged TDP-43 protein is reduced in the screen, it does not alter cryptic exon splicing and there is a longer TDP-43 half-life with BORC KD.

Weaknesses:

While the data is very strong, the work requires some additional clarification.

Reviewer #3 (Public review):

Summary:

In this work, Ryan et al. have performed a state-of-the-art full genome CRISP-based screen of iNEurons expressing a teggd version of TDP-43 in order to determine expression modifiers of this protein. Unexpectedly, using this approach the authors have uncovered a previously undescribed role of the BORC complex in affecting the levels of TDP-43 protein, but not mRNA expression. Taken together, these findings represent a very solid piece of work that will certainly be important for the field.

Strengths:

- BORC is a novel TDP-43 expression modifier that has never been described before and it seemingly acts on regulating protein half life rather than transcriptome level. It has been long known that different labs have reported different half-lives for TDP-43 depending on the experimental system but no work has ever explained these discrepancies. Now, the work of Ryan et al. has for the time identified one of these factors which could account for these differences and play an important role in disease (although this is left to be determined in future studies).
- The genome wide CRISPR screening has demonstrated to yield novel results with high reproducibility and could eventually be used to search for expression modifiers of many other proteins involved in neurodegeneration or other diseases

Weaknesses:

- The fact that TDP-43 mRNA does not change following BORCS6 KD is based on a single qRT-PCR that does not really cover all possibilities. For example, the mRNA total levels may not change but the polyA sites may have switched from the highly efficient pA1 to the less efficient and nuclear retained pA4. There are therefore a few other experiments that could have been performed to make this conclusion more compelling, maybe also performing RNAscope experiments to make sure that no change occurred in TDP-43 mRNA localisation in cells.
- Even assuming that the mRNA does not change, no explanation for the change in TDP-43 protein half life has been proposed by the authors. This will presumably be addressed in future studies: for example, are mutants that lack different domains of TDP-43 equally affected in their half-lives by BORC KD?. Alternatively, can a mass-spec be attempted to see whether TDP-43 PTMs change following BORCS6 KD?